Stockscreener 앱 받기
2.65
3.52%
0.09
전일 마감가:
$2.56
열려 있는:
$2.55
하루 거래량:
1.18M
Relative Volume:
0.53
시가총액:
$897.49M
수익:
$796.85M
순이익/손실:
$30.44M
주가수익비율:
31.47
EPS:
0.0842
순현금흐름:
$93.88M
1주 성능:
+9.05%
1개월 성능:
+11.81%
6개월 성능:
-2.21%
1년 성능:
-30.63%
1일 변동 폭
$2.55
$2.665
1주일 범위
$2.415
$2.665
52주 변동 폭
$1.77
$5.8099
Goodrx Holdings Inc Stock (GDRX) Company Profile
명칭
Goodrx Holdings Inc
전화
(855) 268-2822
주소
2701 OLYMPIC BOULEVARD, SANTA MONICA
Compare GDRX vs VEEV, BTSG, TEM, HQY, HNGE
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GDRX
Goodrx Holdings Inc
|
2.65 | 867.01M | 796.85M | 30.44M | 93.88M | 0.0842 |
VEEV
Veeva Systems Inc
|
160.17 | 25.83B | 3.20B | 908.91M | 1.39B | 5.4168 |
BTSG
Brightspring Health Services Inc
|
58.50 | 11.25B | 13.65B | 169.86M | 412.12M | 1.0758 |
TEM
Tempus Ai Inc
|
46.18 | 8.35B | 1.36B | -302.91M | -219.93M | -1.7182 |
HQY
Healthequity Inc
|
88.11 | 7.25B | 1.31B | 215.20M | 408.32M | 2.4627 |
HNGE
Hinge Health Inc
|
55.25 | 4.27B | 646.34M | -512.40M | 202.76M | -6.6871 |
Goodrx Holdings Inc Stock (GDRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-27 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2026-01-22 | 다운그레이드 | Jefferies | Buy → Hold |
| 2025-12-09 | 개시 | Barclays | Underweight |
| 2025-08-11 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2024-12-04 | 개시 | Mizuho | Neutral |
| 2024-08-09 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2024-05-23 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-05-16 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2024-04-10 | 업그레이드 | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2024-03-25 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-03-01 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2024-02-26 | 개시 | Leerink Partners | Outperform |
| 2024-01-02 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2023-08-10 | 업그레이드 | DA Davidson | Neutral → Buy |
| 2023-07-31 | 업그레이드 | TD Cowen | Market Perform → Outperform |
| 2022-12-01 | 개시 | Citigroup | Buy |
| 2022-11-04 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2022-09-16 | 개시 | KeyBanc Capital Markets | Sector Weight |
| 2022-09-07 | 개시 | Truist | Hold |
| 2022-08-12 | 개시 | DA Davidson | Neutral |
| 2022-06-10 | 다운그레이드 | Goldman | Buy → Neutral |
| 2022-06-06 | 재개 | BofA Securities | Buy |
| 2022-06-01 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2022-05-10 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-05-10 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-05-10 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2022-05-10 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2022-04-11 | 개시 | Wells Fargo | Equal Weight |
| 2022-04-07 | 개시 | Guggenheim | Buy |
| 2022-04-01 | 재개 | Credit Suisse | Neutral |
| 2022-03-15 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2022-03-01 | 재확인 | Barclays | Overweight |
| 2022-03-01 | 재확인 | BofA Securities | Neutral |
| 2022-03-01 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2022-03-01 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2022-03-01 | 재확인 | Evercore ISI | Outperform |
| 2022-03-01 | 재확인 | Goldman | Buy |
| 2022-03-01 | 재확인 | JP Morgan | Underweight |
| 2022-03-01 | 재확인 | RBC Capital Mkts | Outperform |
| 2022-03-01 | 재확인 | SVB Leerink | Outperform |
| 2022-01-07 | 개시 | Goldman | Buy |
| 2021-12-21 | 개시 | Stephens | Overweight |
| 2021-12-02 | 개시 | Jefferies | Buy |
| 2021-08-31 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2021-08-13 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2021-05-28 | 개시 | Robert W. Baird | Neutral |
| 2021-04-06 | 재개 | Evercore ISI | Outperform |
| 2021-01-25 | 개시 | Guggenheim | Buy |
| 2020-11-19 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-18 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-10-19 | 개시 | Barclays | Equal Weight |
| 2020-10-19 | 개시 | BofA Securities | Neutral |
| 2020-10-19 | 개시 | Citigroup | Buy |
| 2020-10-19 | 개시 | Cowen | Outperform |
| 2020-10-19 | 개시 | Credit Suisse | Outperform |
| 2020-10-19 | 개시 | Deutsche Bank | Hold |
| 2020-10-19 | 개시 | Goldman | Neutral |
| 2020-10-19 | 개시 | JP Morgan | Neutral |
| 2020-10-19 | 개시 | Morgan Stanley | Overweight |
| 2020-10-19 | 개시 | RBC Capital Mkts | Sector Perform |
| 2020-10-19 | 개시 | SVB Leerink | Outperform |
| 2020-10-19 | 개시 | UBS | Buy |
모두보기
Goodrx Holdings Inc 주식(GDRX)의 최신 뉴스
SA analyst upgrades/downgrades: NVDA, META, GDRX, JPM - Seeking Alpha
Hims & Hers Deepens Personalized Care Through Platform Expansion - TradingView
GoodRx: Evident Stabilization, But GLP-1 Dependence Is A Risk (Upgrade) (NASDAQ:GDRX) - Seeking Alpha
GoodRx: TrumpRx Exposes Legacy Moat Breach And Zero-Sum Strategy (Downgrade) (NASDAQ:GDRX) - Seeking Alpha
GoodRx (GDRX) Q1 earnings: Taking a look at key metrics versus estimates - MSN
GoodRx Holdings (GDRX) price target increased by 10.24% to 3.17 - MSN
The 5 Most Interesting Analyst Questions From GoodRx’s Q1 Earnings Call - Yahoo Finance
GoodRx (GDRX) CAO exercises RSUs and delivers shares to cover taxes - Stock Titan
GoodRx (NASDAQ: GDRX) executive exercises 44,779 RSUs, 19,726 shares for taxes - Stock Titan
GoodRx Holdings' (NASDAQ:GDRX) Soft Earnings Are Actually Better Than They Appear - Yahoo Finance
GDRX Maintained by Citigroup -- Price Target Raised to $4.00 - GuruFocus
GoodRx Holdings Is Maintained at Buy by Citigroup - Moomoo
Jim Cramer on GoodRx: “I’m Going to Grant You That Spec” - Insider Monkey
Some May Be Optimistic About GoodRx Holdings' (NASDAQ:GDRX) Earnings - simplywall.st
GDRX (NASDAQ: GDRX) Form 144 — 43,100-share proposed sale - Stock Titan
Why Jim Cramer Says 'Pull The Trigger' On Chevron - Benzinga
GoodRx (GDRX) awards 54,494 RSUs to Chief Accounting Officer Thomas Chan - Stock Titan
Earnings call transcript: GoodRx Q1 2026 beats revenue forecast, stock rises By Investing.com - Investing.com South Africa
Earnings call transcript: GoodRx Q1 2026 beats revenue forecast, stock rises - Investing.com Nigeria
TradingKey - TradingKey
Analysts Offer Insights on Healthcare Companies: GoodRx Holdings (GDRX) and DaVita (DVA) - The Globe and Mail
GDRX Maintained by TD Cowen -- Price Target Raised to $4.00 - GuruFocus
symbol__ Stock Quote Price and Forecast - CNN
GoodRx vs. Hims & Hers Health: Stagnation vs. Growth in Revenue - The Motley Fool
GoodRx Holdings, Inc. (NASDAQ:GDRX) Q1 2026 Earnings Call Transcript - Insider Monkey
GoodRx Earnings Call Highlights Pharma Direct Momentum - TipRanks
GoodRx (GDRX) Q1 2026 Earnings Call Transcript - The Globe and Mail
GoodRx (GDRX) Reports Strong Q1 2026 Earnings and Raises Guidance - GuruFocus
GoodRx Q1 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: GoodRx Q1 2026 revenue exceeds forecasts By Investing.com - Investing.com South Africa
Earnings call transcript: GoodRx Q1 2026 revenue exceeds forecasts - Investing.com India
GoodRx Holdings, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Q1 2026 GoodRx Holdings Inc Earnings Call Transcript - GuruFocus
GoodRx Holdings, Inc. (GDRX) Reports In-Line Q1 EPS ; Offers Guidance - StreetInsider
Number of shareholders of GoodRx Holdings, Inc. – NASDAQ:GDRX - TradingView
GoodRx (GDRX) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates - sharewise.com
GoodRx Holdings, Inc. (GDRX) Q1 earnings match estimates - MSN
GoodRx Holdings Inc reports results for the quarter ended March 31Earnings Summary - TradingView
GoodRx Reports First Quarter 2026 Results - pharmiweb.com
GoodRx Holdings, Inc. (GDRX) Q1 Earnings Match Estimates - Yahoo Finance
GoodRx (NASDAQ:GDRX) Beats Q1 CY2026 Sales Expectations - Barchart.com
GDRX: Pharma Direct revenue soared 82% in Q1 2026, offsetting declines in other segments - TradingView
Goodrx Holdings Inc (GDRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.66%
4.05%
자본화:
|
볼륨(24시간):